ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

Therapy resistance is a major clinical problem in cancer medicine and crucial for disease relapse and progression. Therefore, the clinical need to overcome it, particularly for aggressive tumors such as pancreatic cancer, is very high. Aberrant activation of an epithelial–mesenchymal transition (EMT...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EMBO Mol Med
Autors principals: Meidhof, Simone, Brabletz, Simone, Lehmann, Waltraut, Preca, Bogdan-Tiberius, Mock, Kerstin, Ruh, Manuel, Schüler, Julia, Berthold, Maria, Weber, Anika, Burk, Ulrike, Lübbert, Michael, Puhr, Martin, Culig, Zoran, Wellner, Ulrich, Keck, Tobias, Bronsert, Peter, Küsters, Simon, Hopt, Ulrich T, Stemmler, Marc P, Brabletz, Thomas
Format: Artigo
Idioma:Inglês
Publicat: BlackWell Publishing Ltd 2015
Matèries:
Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4459821/
https://ncbi.nlm.nih.gov/pubmed/25872941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201404396
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars